QualityStocksNewsBreaks – Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
VERAXA Biotech (NASDAQ: VRXA) is advancing a diversified oncology pipeline spanning monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based therapeutic formats across multiple cancer indications. “The company is focused on the discovery and development of a new generation of antibody-based therapeutics for the treatment of solid tumors. VERAXA’s vision is to deliver the next wave of smart cancer therapies with curative potential and improved safety profiles,” reads a recent article. “The company is building a pipeline that includes dual-targeting antibody-drug conjugates (‘ADCs’) and T-cell engagers (‘TCEs’) predominantly based on its patented BiTAC concept. This concept is designed to improve the…